



Leveraging **EGFR MUTATION**
Profiles to Personalize
Therapeutic Decisions in
Resected and Metastatic
NSCLC Settings

FRIDAY, JUNE 3, 2022

6:30 PM - 8:30 PM CDT

PROGRAM CHAIR

Edward B. Garon, MD, MS

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoper.

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: Leveraging *EGFR* Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings**.

Patients with *EGFR*-mutated non-small cell lung cancer (NSCLC) represent a unique population within oncology due to an expanding array of treatment options tailored to individual cases. In order to optimize therapy, clinicians need to navigate critical decision points throughout the continuum of care, including diagnosis, molecular testing, and selection of treatment. This live symposium brings together renowned experts in the management of NSCLC to discuss best practices for the care of patients with *EGFR*-mutated lung cancer. The dynamic format Medical Crossfire® format encourages discussion about interactions and decisions faced by clinicians within the multidisciplinary team.

In working together with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with NSCLC.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope that you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Edward B. Garon, MD, MS

Professor of Medicine (Hematology/Oncology)
David Geffen School of Medicine at University of California, Los Angeles
UCLA Health
Los Angeles, CA

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

6:30 PM	Welcome, Introductions, and Presession Survey	Edward Garon, MD, MS
6:40 PM	<i>EGFR</i> Mutation-Positive NSCLC as a Unique Population of Patients	Edward Garon, MD, MS
7:00 PM	Medical Crossfire®: Choosing First-Line Therapy for Patients With Metastatic, <i>EGFR</i> Mutation-Positive NSCLC	Lyudmila Bazhenova, MD
7:20 PM	Medical Crossfire®: Managing <i>EGFR</i> Mutation-Positive NSCLC in the Presence of Co-mutations	Zofia Piotrowska , MD, MHS
7:40 PM	Medical Crossfire®: Bringing EGFR Inhibition to Resectable NSCLC	Solange Peters, MD, PhD
8:00 PM	Postsession Survey	Edward Garon, MD, MS
8:05 PM	Panel Discussion and ASCO Preview	Edward Garon, MD, MS Lyudmila Bazhenova, MD Zofia Piotrowska , MD, MHS Solange Peters, MD, PhD
8:20 PM	Question-and-Answer Session	Edward Garon, MD, MS Lyudmila Bazhenova, MD Zofia Piotrowska , MD, MHS Solange Peters, MD, PhD
8:30 PM	Adjourn	

Upcoming PER® Conferences			2022
●	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
●	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
●	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
●	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
●	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
●	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
●	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
●	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
●	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
●	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10

● Virtual Conference

● In-Person + Virtual Conference

Target Audience

These activities are intended for oncologists, pathologists, and related health care professionals interested in the latest advances in the diagnosis, treatment, and management of lung cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Discuss the role of multidisciplinary team members in addressing barriers to testing and the interpretation of molecular test results for patients with early stage and metastatic NSCLC
- Summarize high-risk genomic co-mutations that occur in patients with *EGFR* mutation-positive NSCLC
- Assess outcomes among *EGFR* mutation profiles with the application of different EGFR inhibitor-based monotherapy and combination regimens
- Apply approaches to mitigate and manage treatment-related toxicities associated with the use of targeted therapy in patients with early stage and metastatic NSCLC

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/fl-egfr0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/fl-egfr0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 3, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

Thank you for attending **Medical Crossfire®: Leveraging *EGFR* Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Shareholder
Lyudmila Bazhenova, MD	To institution: BeyondSpring	Janssen, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Bristol Myers Squibb, Merck, NEUVOGEN, ORIC	Epic Sciences
Edward B. Garon, MD, MS	AstraZeneca, Bristol Myers Squibb, Dynavax Technologies, Eli Lilly, EMD Serono, Genentech, Iovance Biotherapeutics, Merck, Mirati Therapeutics, Neon, Novartis	ABL-Bio, Boehringer-Ingelheim, Bristol Myers Squibb, Dracen Pharmaceuticals, EMD Serono, Eisai, GlaxoSmithKline, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio	
Solange Peters, MD, PhD	Institutional financial support for clinical trials: Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co, Roche/Genentech	Consultation/Advisory role: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GlaxoSmithKline, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Merck & Co, Merck Serono, Merrimack, Novartis, Novocure, Pharma Mar, Phosphatin Therapeutics, Pfizer, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, SeaGen, Takeda. Speaker: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda.	
Zofia Piotrowska, MD, MHS	AstraZeneca, Novartis, Spectrum, Takeda, Cullinan Oncology, Daiichi Sankyo, AbbVie, Janssen, Tesaro/GlaxoSmithKline	Daiichi Sankyo, C4 Therapeutics, Cullinan, Takeda, Janssen, Blueprint, Jazz	

**Information accurate at time of posting*


PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Experience
the new
goto**per**.com



Streamlining
education
for the busy
clinician



Program Chair



Edward B. Garon, MD, MS

Professor of Medicine (Hematology/Oncology)

David Geffen School of Medicine at the University of California, Los Angeles
Los Angeles, CA

Dr Garon received his medical degree from the Washington University School of Medicine and his internal medicine training at the University of Chicago. He trained in medical oncology at the University of California, Los Angeles, where he also received a masters' degree in clinical investigation. Dr Garon was awarded the Diana Gordon Jonnson Award for Clinical Excellence. In addition to his clinical work, he has an extensive focus on clinical and translational research. He has led studies that have resulted in FDA approvals of multiple drugs and companion diagnostics. Dr Garon has received multiple foundation grants and peer-reviewed grants from governmental agencies, including the National Institutes of Health.

Faculty



Lyudmila Bazhenova, MD

Clinical Professor of Medicine

Director, Hematology Oncology Training Program

Lung Cancer Team Leader

Moore's Cancer Center

UC San Diego Health

La Jolla, CA

Lyudmila A. Bazhenova, MD, believes in a multidisciplinary approach to lung cancer and works closely with surgical and radiation oncologists. Her clinical practice is devoted to patients with all types of lung cancer, and she has particular expertise with female patients and nonsmokers. She leads a weekly "lung tumor board," where expert physicians and scientists from several specialties review cases to develop optimal individualized treatment plans. Dr Bazhenova earned her medical degree from Nizhny Novgorod State Medical Academy in Russia and completed a fellowship in hematology and oncology at Scripps Clinic Green Hospital and a residency in internal medicine at the VA Greater Los Angeles Healthcare System. Dr Bazhenova is involved in designing and implementing clinical investigations at Moore's Cancer Center. These phase 2 studies and correlative science projects often connect patients with newly approved therapies or treatments available only in clinical trials.

**Solange Peters, MD, PhD**

Professor of Medicine
Chair, Thoracic Malignancies
Head, Medical Oncology
Oncology Department
Lausanne University Hospital
Lausanne, Switzerland

Solange Peters, MD, PhD, is a professor and the head of medical oncology at the faculty of Biology and Medicine at the Lausanne University Hospital in Switzerland. She currently leads teaching and patient care in medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, where she is collaborating with the molecular oncology laboratories of the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute to build a translational program. Dr Peters achieved her medical degree from the University of Lausanne, where she then attended the Microbiology Institute; she completed her residency in internal medicine and a fellowship at the Multidisciplinary Oncology Centre at the university hospital. Her main interest is discovery and validation of new biomarkers in preclinical and clinical settings. Dr Peters is also strongly interested in multimodality trial building for locally advanced non-small cell lung cancer (NSCLC) and clinical and translational cancer immunotherapy. Her current research projects are focused on multimodality curative-intent treatment of stage III NSCLC, combined immunotherapy to treat NSCLC, small cell lung cancer, thymic malignancies, and mesothelioma and targeted therapies in oncogene-addicted NSCLC. She acts as the local principal investigator of lung trials opened at the Lausanne Cancer Centre and is focused on phase 1 predictive biomarkers and NSCLC immunotherapy. She also is a co-PI of several other trials.

**Zofia Piotrowska, MD, MHS**

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Dr Piotrowska is an attending thoracic medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School. Dr Piotrowska's research focuses on understanding mechanisms of acquired resistance and developing novel therapies for both non-small and small cell lung cancer. She is the lead investigator of national and international lung cancer clinical trials, and she has received grant support from the LUNGEvity Foundation, the American Cancer Society, and Uniting Against Lung Cancer. She received her medical degree from the Yale University School of Medicine and trained in internal medicine at Brigham and Women's Hospital and in hematology/oncology at Dana Farber Cancer Institute and Massachusetts General Hospital.



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC

40th Annual
CFS®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY

In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.



100 EXPERT
FACULTY
MEMBERS



25 TUMOR
TYPES



3 DAYS



1 MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com